CSBR vs IDXX vs ZTS vs IMVT

For growth investors, Champions Oncology, Inc.

(CSBR) is the stronger pick with 13. 5% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 14. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 14. 5x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Zoetis Inc. is actually cheaper at 12. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 04x versus IDEXX Laboratories, Inc. 's 2. 76x — a reasonable growth-adjusted valuation.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -44. 4% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus CSBR's +47. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Champions Oncology, Inc.

(CSBR) is the lower-risk stock at 0. 38β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 258% more volatile than CSBR relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Champions Oncology, Inc.

(CSBR) is pulling ahead at 13. 5% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Champions Oncology, Inc. grew EPS 161. 1% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 04x versus IDEXX Laboratories, Inc. 's 2. 76x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 12. 4x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 27. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMVT: 67. 2% to $45. 50.

In this comparison, ZTS (2.

3% yield) pays a dividend. CSBR, IDXX, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 2. 3% yield, +107. 3% 10Y return). Both have compounded well over 10 years (ZTS: +107. 3%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CSBR is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock; IMVT is a small-cap quality compounder stock. ZTS pays a dividend while CSBR, IDXX, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.